Research and Markets (http://www.researchandmarkets.com/research/dsdfsr/epicast_report)
has announced the addition of the "EpiCast
Report: Graft-Versus-Host Disease - Epidemiology Forecast to 2023"
report to their offering.
Graft-versus-host disease (GVHD) is a common complication of allogeneic
hematopoietic stem cell transplantation (HSCT) that occurs when the
donated (graft) cells are rejected and attack the host's cells as
foreign. GVHD can progress from mild to severe forms as either acute
GVHD (aGVHD) or chronic GVHD (cGVHD). Both aGVHD and cGVHD commonly
affect organs such as the skin, gastrointestinal (GI) tract, liver, oral
mucosa, and eyes.
To forecast the diagnosed incident cases of aGVHD and cGVHD in the 6MM,
GlobalData epidemiologists selected nationally-representative studies
that provided the diagnosed incidence of aGVHD and cGVHD using the
uniform validated diagnostic criteria and classification defined by the
Center International Blood and Marrow Transplant Research standard
grading system for aGVHD, and the standard criteria for cGVHD. In this
analysis, GlobalData epidemiologists provided detailed, clinically
relevant segmentations for the diagnosed aGVHD and cGVHD cases. Another
strength of this analysis is that the same methodology was used across
the 6MM, thereby allowing for meaningful global comparisons of the
diagnosed incident GVHD cases.
Reasons to buy:
Key Topics Covered:
1 Table of Contents
For more information visit http://www.researchandmarkets.com/research/dsdfsr/epicast_report
[ Back To NFVZone's Homepage ]